Connor F.I., Di Lorenzo C. Chronic Intestinal Pseudo-obstruction: Assessment and Management // Gastroenterology. 2006. Vol. 130, No. 2. P. S29–S36.

Популярно о болезнях ЖКТ Лекарства при болезнях ЖКТ Если лечение не помогает Адреса клиник

Авторы: Connor F.I. / Di Lorenzo C.



Chronic Intestinal Pseudo-obstruction: Assessment and Management

Frances L. Connor* and Carlo Di Lorenzo**

*Division of Pediatric Gastroenterology, and the Division of Hepatology and Nutrition, Royal Children’s Hospital, Herston, Australia; and

**Columbus Children’s Hospital, Columbus, Ohio


The spectrum of motility disorders ranges from relatively benign conditions such as gastroesophageal reflux and functional dyspepsia to life-threatening illnesses such as chronic intestinal pseudo-obstruction (CIPO). Motility disorders account for up to 15% of pediatric patients with intestinal failure.1 In other more common causes of intestinal failure, such as short gut syndrome, abnormal motility also plays an important role in determining whether patients will be able to be weaned from parenteral nutrition. Pseudo-obstruction represents the most severe form of motility disorder and may be considered an insufficiency of the intestinal pump, very much like heart failure is caused by an insufficiency of the cardiac pump. Although this review focuses mostly on CIPO, much of the information about pathophysiology and diagnostic and therapeutic approaches is applicable to other less severe forms of motility disorders.

Pseudo-obstruction may be congenital or acquired, primary or secondary (Table 1).2 In most pediatric cases, symptoms are present from birth or early infancy.3 Regardless of the underlying cause, 2 main groups can be identified based on histopathology and patterns of motility abnormalities: visceral myopathy and visceral neuropathy. Neuropathic disorders are more common and may be primary (sometimes familial) or secondary (eg, in utero insults such as fetal alcohol syndrome or postnatal injuries such as ischemic events or viral infections). Mitochondrial disorders such as mitochondrial neurogastroencephalopathy also may be complicated by neuropathic pseudo-obstruction,4 with the gastrointestinal symptoms often preceding the neurologic dysfunction. Recently, abnormalities of the gastrointestinal pacemaker cells, the interstitial cells of Cajal, have been described in patients with motility disorders.5–8 Functionally, these patients may have features of both myopathy and neuropathy. Motility problems also may complicate structural gastrointestinal abnormalities. Patients with a history of malrotation, atresia, enterocolitis, or gastroschisis repair frequently have abnormal motility in the remaining gut, limiting tolerance of enteral feeds even when the length of residual small bowel apparently is sufficient.3 Animal studies have shown that ischemic insults and exposure to amniotic fluid have additive deleterious effects on gastrointestinal motility, with the potential to cause long-term dysfunction. 9–12 Damage is progressive throughout gestation.10 However, in human beings, deliberate premature delivery of fetuses affected by gastroschisis has not been found to be beneficial.13

Treatable causes of CIPO are rare but should be considered in every case because of the potential value of specific therapy. In some cases of delayed maturation of the enteric nervous system or of the interstitial cells of Cajal, resolution may be spontaneous.8 In other conditions such as celiac disease,14 hypothyroidism,15,16 Kawasaki disease,17 and cystic fibrosis with meconium ileus or distal intestinal obstruction syndrome, treatment of the underlying disease may improve or reverse severe dysmotility. Pseudo-obstruction has been described in association with DNA viruses such as Herpes simplex, Epstein-Barr virus, and cytomegalovirus.18–20 Such cases of dysmotility after specific viral infections theoretically may respond to antiviral therapy, although clinical data are lacking. Rare cases of autoimmune myositis also have been reported with symptoms of pseudo-obstruction improving with corticosteroid therapy.21 Similarly, some cases of CIPO in children and young adults appear to be caused by autoimmune lymphocytic destruction of myenteric ganglia.22,23 In these cases, anti-Hu (antineuronal nuclear, ANNA-1) antibodies appear to be a useful serologic marker.22,23 Cases of eosinophilic myenteric gan-glionitis also have been described.24 Although uncommon, these inflammatory and autoimmune cases are important to identify because they may respond to anti-inflammatory medications.22–24

Table 1. Causes of Chronic Intestinal Pseudo-obstruction

Table 1. Causes of Chronic Intestinal Pseudo-obstruction

Assessment Radiology

In CIPO, abdominal radiographs may show dilated loops of small bowel and air-fluid levels, except in patients who are not being fed and have venting enterostomies. Contrast radiology should be performed using water-soluble material to avoid the formation of barium concretions in the colon. Upper gastrointestinal series with small-bowel follow-through studies show dilated loops of bowel with very slow transit through a featureless intestine (Figure 1). Because contrast material often becomes diluted in fluid-filled bowel loops, recognition of mucosal details and detection of partial bowel obstruction may be arduous.

Manometry

Antroduodenal manometry is used to determine the pathophysiology of symptoms in CIPO.25 Antroduodenal manometry assesses contraction amplitude and spatial and temporal organization of phasic contractions. The presence of normal patterns, such as the migrating motor complex in fasting (Figure 2), and a change to postprandial motility pattern with a test meal indicate intact enteric neuromuscular function. Manometry is useful to distinguish myopathy, in which contraction amplitude is reduced but spatial and temporal organization is preserved (Figure 3), from neuropathy, in which contractions have normal amplitude but are uncoordinated and lack normal physiologic patterns. Intrinsic or visceral neuropathy is characterized by abnormal (Figure 4) or even absent phase III of the migrating motor complex, the most recognizable motor pattern during fasting. A normal motor response to food is dependent on the integrity of both intrinsic and extrinsic neural control systems, and the gastrointestinal smooth muscle. In the presence of normal amplitude contractions, an impaired or even absent motor response to food may occur in both visceral neuropathy and extrinsic autonomic neuropathy.26 In the presence of severe, long-standing disease with intestinal dilatation, antroduodenal manometry recordings may be nonspecific, with negligible contractile activity detected.

Figure 1. Upper-gastrointestinal series with small-bowel follow-through in a child with CIPO. Note the dilated loops of (A) small bowel and the (B) slow transit with dilution of the contrast material

Figure 1. Upper-gastrointestinal series with small-bowel follow-through in a child with CIPO. Note the dilated loops of (A) small bowel and the (B) slow transit with dilution of the contrast material

Figure 2. Phase III motor migrating complex originating from the antrum and migrating distally

Figure 2. Phase III motor migrating complex originating from the antrum and migrating distally

Figure 3. Manometric tracing from a child with hollow visceral myopathy. Amplitude of contractions is less than 50 mm Hg in the antrum and less than 20 mm Hg in the duodenum

Figure 3. Manometric tracing from a child with hollow visceral myopathy. Amplitude of contractions is less than 50 mm Hg in the antrum and less than 20 mm Hg in the duodenum

Figure 4. Manometric tracing from a child with visceral neuropathy. There is evidence of abnormal configuration of a phase III motor migrating complex with some retrograde migration (third recording site from above) and lack of propagation (most distal recording site)

Figure 4. Manometric tracing from a child with visceral neuropathy. There is evidence of abnormal configuration of a phase III motor migrating complex with some retrograde migration (third recording site from above) and lack of propagation (most distal recording site)

Antroduodenal manometry also may be used to suggest prognosis 27 and likely response to treatment. 28 If the migrating motor complex is present, patients are likely to tolerate enteral feeding. 29 Similarly, the presence of phase III of the migrating motor complex is associated with a favorable response to prokinetic therapy with cisapride. 28 In patients showing symptoms of intestinal pseudo-obstruction, the presence of normal manometry studies should lead to the consideration of emotional or factitious disorders.30,31

Frequently, the severity of motility dysfunction varies throughout the gastrointestinal tract. Motility studies may identify areas with preserved motility and different feeding strategies then may be devised, bypassing the affected segments. For example, if the stomach is more affected than the small bowel, gastrojejunal or jejunostomy feedings may be better tolerated.29 Motility studies of the rest of the gut, including colonic manometry and/or radiopaque marker studies, may show distal mo-tility impairment. In such cases, a defunctioning ileos-tomy may decompress the gut, increasing the ability to receive enteral feeds. When both the upper and lower gastrointestinal tract are diseased, a colectomy is less likely to be beneficial,32 although we believe that abnormal foregut motility is not an absolute contraindication to placement of an ileostomy in CIPO. Esophageal manometry may be abnormal both in children and adults with CIPO.33,34

Transit Studies

Transit studies document prolonged whole-gut transit times in CIPO.3 Radioopaque marker studies may be useful to identify the site of functional obstruction in CIPO. In a child with pseudo-obstruction related to neuronal intestinal dysplasia, marker studies indicated a hold-up in the ascending colon. The child did well after defunctioning ileostomy.35 Scintigraphic studies have been used in adults to measure gastric, small-bowel, and colonic transit. Patterns of ileocolonic transfer of solid chyme may suggest the underlying pathophysiology. It was noted that bolus filling of the colon was less frequent in patients with myopathic CIPO whereas it was preserved in patients with neuropathic CIPO.36 Scinti-graphic evaluation of small-bowel transit also has been used to characterize subgroups of children with functional dyspepsia.37

Electrogastrography

Electrogastrography was used previously as a screening test for motility abnormalities. However, results are nonspecific, correlate poorly with symptoms, and there is considerable overlap between children with motility abnormalities and controls.38 Therefore, this technique has lost some of its appeal and manometry is now considered a more definitive investigation for pseudoobstruction.39

Pathology

Increasingly, full-thickness biopsy specimens are obtained to seek a specific pathologic diagnosis. As the range of therapies for CIPO continues to expand, more informative classifications may be necessary to guide management. Biopsy samples should be analyzed in referral laboratories for a wide range of known abnormalities. The biopsy sample should be divided to send some tissue for routine light microscopy (in formalin), some for electron microscopy (in glutaraldehyde), and samples for immunohistochemistry and enzyme histochemistry (snap-frozen).3 Immunoreactivity for c-Kit is a marker for interstitial cells of Cajal and it has been used to show abnormalities in interstitial cells of Cajal distribution in children with CIPO.40 Mitochondrial abnormalities may be suggested by megamitochondria in myenteric ganglion cells from rectal suction or full-thickness biopsy specimens4 and increased serum lactate, pyruvate, and thymidine levels. Mitochondrial DNA from skeletal muscle confirms the presence of mutations.4 If available through research programs, investigations such as in situ hybridization for specific abnormalities may be diagnostic. For example, in situ hybridization on biopsy specimen tissue from patients with megacystis microcolon hypoperistalsis syndrome may show abnormalities of the nicotinic acetylcholine receptor.41

Therapy

Treatment of patients with CIPO requires a multidisciplinary effort with participation of pediatricians, gastroenterologists, dietitians, surgeons, mental health personnel, occupational therapists, speech pathologists, and other subspecialists based on the presence of comorbidities.

Medical Treatment

Prokinetic therapy with cisapride, erythromycin, octreotide, and tegaserod should be attempted. Cisapride increases the antroduodenal motility index 42 and may improve tolerance of enteral feeds.28 Unfortunately, the cardiac toxicity of cisapride led to its withdrawal from sale in most countries. Erythromycin mimics the proki-netic hormone, motilin, and induces phase III of the migrating motor complex in patients capable of generating it.43,44 It has been used in subantibiotic doses with benefit in CIPO.45 Higher doses may be needed in severe cases of gastroparesis. Octreotide is the most potent enterokinetic medication currently available. It stimulates small intestinal motility, inhibits gastric emptying and gallbladder contractility, and has been found to be beneficial in adult patients with CIPO and bacterial overgrowth.46 The inhibition of gastric emptying is mitigated by pretreatment with erythromycin 44 and combination therapy may be beneficial.

Tegaserod, a prokinetic with a similar mode of action to cisapride but no cardiac toxicity, recently has been licensed for use in adults with chronic constipation and may be helpful particularly in patients with colonic involvement. The acetylcholinesterase inhibitor neostigmine is effective therapy for acute colonic pseudo-obstruction in adults and in children.47 Recently, repeated use reportedly was successful in an adult patient with chronic symptoms,48 although chronic use in children with chronic pseudoobstruction has not yet been described.

Abnormal motility is associated with bacterial over-growth,49,50 which by itself causes mucosal inflammation, further impairing gastrointestinal motility and creating a vicious cycle.51 Treatment with antibiotics may improve motility.52,53 A variety of antibiotic regimens have been recommended,54 although controlled clinical data are few. Most clinicians use 1- to 2-week cycles of broad-spectrum antibiotics such as amoxicillin and clavulanic acid, cotrimoxazole, and metronidazole, often with an antifungal such as nystatin or fluconazole, interspersed by antibiotic-free periods.

Chronic abdominal pain or the fear of pain is a common problem in children with CIPO.55 Luminal dilatation, repeated invasive procedures, and mucosal inflammation all may contribute to the development of visceral hyperalgesia with sensitization of peripheral and central pain pathways.56-59 The stress of chronic disease also contributes to pain amplification and altered family dynamics, and poor coping skills may play an important role in determining the degree of functional impairment.60 The presence of severe pain often triggers adversarial relationships between patients, their families, and physicians. The physicians may aim to avoid the use of narcotics that further impair motility, whereas patients seek immediate symptom relief. Such problems are best approached in the context of a multidisciplinary treatment that includes behavioral or relaxation therapy and the use of nonnarcotic medicines.31 The increased understanding of the pathophysiologic disturbances responsible for many functional bowel disorders is now uncovering many putative therapeutic targets for treatment of visceral pain both at the level of the peripheral and central nervous system.61 These include cholecystokinin A antagonists, several serotonergic agonists and antagonists, selective к agonists, tachykinin receptor antagonists, somatostatin analogues, cannabinoids, and γ amino butyric acid receptor modulators.61 Other centrally acting medications, such as gabapentin and tricyclic anti-depressants, also may be beneficial when pain constitutes the predominant symptom.62–66

Surgery

Gastrostomy, jejunostomy, or loop enterostomy may be required to shorten the gut and facilitate transit of intraluminal contents. Such interventions reduce distension, reduce vomiting, and improve quality of life in patients with CIPO on total parenteral nutrition (TPN).67–70

The ability to tolerate enteral feedings may improve,35,71 and the frequency of hospital admissions for obstructive symptoms is reduced.70 In one series of children with CIPO the placement of an ileostomy reduced symptoms in 50%.3 Percutaneous endoscopic colostomy has been successful recently in relieving distension in a group of adult patients with CIPO.72 Resection of localized segments of impaired motility may improve symptoms and decrease the need for parenteral nutrition.68,73 Most affected segments may be identified by radiologic contrast studies, manometry, or by finding localized massive dilatation at laparotomy.73

Transplantation

Small intestinal transplantation is indicated in TPN-dependent pseudo-obstruction patients with lifethreatening complications of TPN or with dwindling venous access.74 Life-threatening complications of TPN include recurrent sepsis and thromboembolic disease. The presence of cholestatic liver disease is also an important indication for early referral for assessment at a transplant center because of the increased mortality rate associated with this condition.75 Conversely, patients who are stable on TPN are best managed without transplantation because survival rates are similar to those posttransplantation.76 The assessment of candidates before intestinal transplantation should include a thorough investigation of the extent of dysmotility and associated abnormalities. Antroduodenal manometry is useful to evaluate foregut function. In the presence of preserved gastric motility, isolated small-bowel transplant is preferred. However, if stomach motility is impaired severely, multivisceral transplantation is warranted. Other associated conditions such as obstructive uropathy (frequently present in children with gastrointestinal myopathies), cholestatic liver disease, and multiple vascular thromboses require a detailed preoperative assessment to plan appropriate intervention.

Outcomes in series of patients transplanted for CIPO reflect outcomes of other small intestinal transplant recipients in the same epochs.77,78 In recent years, children receiving isolated intestinal transplants for intestinal failure have 1-year survival rates of approximately 83%. Small infants fare significantly worse, whereas survival is 90% in children aged 2 years and older.74 The presence of abnormal esophageal and bladder function and longstanding visceral pain affecting some patients with CIPO make the postoperative management more challenging in these patients. Early discontinuation of narcotics is particularly important in an attempt to optimize the allograft bowel motility.

Others

A fascinating and promising therapeutic approach to CIPO involves the use of gastric and intestinal pace-makers.79 The initial results of gastric electric pacing in adults with different causes of gastroparesis have been encouraging. Gastric pacing involves the use of a high-frequency/low-energy electrical stimulation via electrodes implanted in the muscle wall of the antrum. Insertion of the electrodes is performed either by lapa-roscopy or laparotomy. The electrodes then are connected to a neurostimulator that is implanted externally or subcutaneously. The use of the pacemaker has been associated with significant improvement in nausea and vomiting.80,81 Less impressive has been the effect on gastric emptying, suggesting that the electrical stimulation may stimulate sensory rather than motor neurons.

Recent data also suggest an improvement in pancreatic exocrine function82 and nutritional parameters.83 The gastric pacemaker has been approved by the US Food and Drug Administration for use in human beings through the humanitarian device exemption, a category that applies to devices intended to benefit fewer than 4000 patients. Small-bowel pacing is more challenging because of the length of the organ to be stimulated, and it is still in its infancy.

The use of botulinum toxin injection in the pylorus and anus has been used to improve transit through those sphincters.84 Hyperbaric oxygenation has been reported to be beneficial in a child with myopathic CIPO who had presented with abdominal distension and obstructive symptoms.85

Outcome

Despite ongoing improvements in nutrition, medical, and surgical therapies, children with CIPO are plagued by significant morbidity and mortality. Many are born prematurely, and many others have associated abnormalities such as urologic disorders, dysautonomia, and structural gastrointestinal abnormalities such as mal-rotation.86 Liver disease and sepsis, complications of TPN, are the most common causes of death. A recent study of 85 children with congenital CIPO found a 25% mortality rate at a median follow-up time of 2 years.86 In an earlier study, the presence of midgut malrotation, short small intestine, urinary system involvement, onset under 1 year of age, and myopathy on histology were poor prognostic factors (associated with prolonged TPN dependence or death).3 Children with CIPO and their families have a significantly reduced quality of life compared with healthy controls and children with other chronic illnesses.87 However, survival and quality of life are improving. With earlier recognition and aggressive nutritional and medical management, survival into adult life and even pregnancy increasingly is achieved.88,89

References

  1. Guarino A, De Marco G, Italian National Network for Pediatric Intestinal Failure. Natural history of intestinal failure, investigated through a national network-based approach. J Pediatr Gastroen-terol Nutr 2003;37:136–141.
  2. Rudolph CD, Hyman PE, Altschuler SM, Christensen J, Colletti RB, Cucchiara S, Di Lorenzo C, Flores AF, Hillemeier AC, McCallum RW, Vanderhoof JA. Diagnosis and treatment of chronic intestinal pseudo-obstruction in children: report of consensus workshop. J Pediatr Gastroenterol Nutr 1997;24:102–112.
  3. Heneyke S, Smith VV, Spitz L, Milla PJ. Chronic intestinal pseudo-obstruction: treatment and long term follow up of 44 patients. Arch Dis Child 1999;81:21–27.
  4. Teitelbaum JE, Berde CB, Nurko S, Buonomo C, Perez-Atayde AR, Fox VL. Diagnosis and management of MNGIE syndrome in children: case report and review of the literature. J Pediatr Gastroenterol Nutr 2002;35:377-383.
  5. Streutker CJ, Huizinga JD, Campbell F, Ho J, Riddell RH. Loss of CD117 (c-kit)- and CD34-positive ICC and associated CD34-positive fibroblasts defines a subpopulation of chronic intestinal pseudo-obstruction. Am J Surg Pathol 2003;27:228-235.
  6. Jain D, Moussa K, Tandon M, Culpepper-Morgan J, Proctor DD. Role of interstitial cells of Cajal in motility disorders of the bowel. Am J Gastroenterol 2003;98:618-624.
  7. Isozaki K, Hirota S, Miyagawa J, Taniguchi M, Shinomura Y, Matsuzawa Y. Deficiency of c-kit+ cells in patients with a myo-pathic form of chronic idiopathic intestinal pseudo-obstruction. Am J Gastroenterol 1997;92:332-334.
  8. Kenny SE, Vanderwinden JM, Rintala RJ, Connell MG, Lloyd DA, Vanderhaegen JJ, De Laet MH. Delayed maturation of the interstitial cells of Cajal: a new diagnosis for transient neonatal pseudo-obstruction. Report of two cases. J Pediatr Surg 1998; 33:94-98.
  9. Srinathan SK, Langer JC, Blennerhassett MG, Harrison MR, Pelletier GJ, Lagunoff D. Etiology of intestinal damage in gastroschisis. Ill: morphometric analysis of the smooth muscle and submucosa. J Pediatr Surg 1995;30:379-383.
  10. Langer JC, Bell JG, Castillo RO, Crombleholme TM, Longaker MT, Duncan BW, Bradley SM, FinkbeinerWE, Verrier ED, Harrison MR. Etiology of intestinal damage in gastroschisis, II. Timing and reversibility of histological changes, mucosal function, and contractility. J Pediatr Surg 1990;25:1122-1126.
  11. Langer JC, Longaker MT, Crombleholme TM, Bond SJ, Finkbeiner WE, Rudolph CA, Verrier ED, Harrison MR. Etiology of intestinal damage in gastroschisis. I: Effects of amniotic fluid exposure and bowel constriction in a fetal lamb model. J Pediatr Surg 1989; 24:992-997.
  12. Oyachi N, Lakshmanan J, Ross MG, Atkinson JB. Fetal gastrointestinal motility in a rabbit model of gastroschisis. J Pediatr Surg 2004;39:366-370.
  13. Simmons M, Georgeson KE. The effect of gestational age at birth on morbidity in patients with gastroschisis. J Pediatr Surg 1996; 31:1060-1062.
  14. Dawson D, Sciberras C, Whitwell J. Coeliac disease presenting with intestinal pseudo-obstruction. Gut 1984;25:1003-1008.
  15. Bassotti G, Pagliacci MC, Nicoletti I, Pelli MA, Morelli A. Intestinal pseudoobstruction secondary to hypothyroidism. Importance of small bowel manometry. J Clin Gastroenterol 1992;14:56-58.
  16. Abbasi AA, Douglass RC, Bissell GW, Chen Y. Myxedema ileus. A form of intestinal pseudo-obstruction. JAMA 1975;234:181-183.
  17. Akikusa JD, Laxer RM, Friedman JN. Intestinal pseudoobstruction in Kawasaki disease. Pediatrics 2004;113:e504-e506.
  18. Sonsino E, Mouy R, Foucaud P, Cezard JP, Aigrain Y, Bocquet L, Navarro J. Intestinal pseudoobstruction related to cytomegalovirus infection of myenteric plexus. N Engl J Med 1984;311:196-197.
  19. Ategbo S, Turck D, Gottrand F, Bonnevalle M, Wattre P, Lecomte-Houcke M, Farriaux JP. Chronic intestinal pseudo-obstruction associated with cytomegalovirus infection in an infant. J Pediatr Gastroenterol Nutr 1996;23:457-460.
  20. Debinski HS, Kamm MA, Talbot IС, Khan G, Kangro HO, Jeffries DJ. DNA viruses in the pathogenesis of sporadic chronic idiopathic intestinal pseudo-obstruction. Gut 1997;41:100-106.
  21. Ginies JL, Francois H, Joseph MG, Champion G, Coupris L, Limal JM. A curable cause of chronic idiopathic intestinal pseudo-obstruction in children: idiopathic myositis of the small intestine. J Pediatr Gastroenterol Nutr 1996;23:426-429.
  22. Smith VV, Gregson N, Foggensteiner L, Neale G, Milla PJ. Acquired intestinal aganglionosis and circulating autoantibodies without neoplasia or other neural involvement. Gastroenterology 1997;112:1366-1371.
  23. De Giorgio R, Barbara G, Stanghellini V, De Ponti F, Salvioli B, Tonini M, Velio P, Bassotti G, Corinaldesi R. Clinical and morpho-functional features of idiopathic myenteric ganglionitis underlying severe intestinal motor dysfunction: a study of three cases. Am J Gastroenterol 2002;97:2454–2459.
  24. Schappi MG, Smith VV, Milla PJ, Lindley KJ. Eosinophilic myen-teric ganglionitis is associated with functional intestinal obstruction. Gut 2003;52:752–755.
  25. Hyman PE, McDiarmid SV, Napolitano J, Abrams CE, Tomomasa T. Antroduodenal motility in children with chronic intestinal pseudo-obstruction. J Pediatr 1988;112:899–905.
  26. Wingate D. Small bowel manometry. Am J Gastroenterol 1995; 90:536–539.
  27. Fell JM, Smith VV, Milla PJ. Infantile chronic idiopathic intestinal pseudo-obstruction: the role of small intestinal manometry as a diagnostic tool and prognostic indicator. Gut 1996;39:306–311.
  28. Hyman PE, Di Lorenzo C, McAdams L, Flores AF, Tomomasa T, Garvey TQ 3rd. Predicting the clinical response to cisapride in children with chronic intestinal pseudo-obstruction. Am J Gastro-enterol 1993;88:832–836.
  29. Di Lorenzo C, Flores AF, Buie T, Hyman PE. Intestinal motility and jejunal feeding in children with chronic intestinal pseudo-obstruction. Gastroenterology 1995;108:1379–1385.
  30. Hyman PE, Bursch B, Beck D, DiLorenzo C, Zeltzer LK. Discriminating pediatric condition falsification from chronic intestinal pseudo-obstruction in toddlers. Child Maltreatment 2002;7:132–137.
  31. Hyman PE. Chronic intestinal pseudo-obstruction. In: Hyman PE, ed. Pediatric gastrointestinal motility disorders. Volume 1. New York: Academy Professional Information Services, Inc., 1994: 115–128.
  32. Glia A, Akerlund JE, Lindberg G. Outcome of colectomy for slow-transit constipation in relation to presence of small-bowel dys-motility. Dis Colon Rectum 2004;47:96–102.
  33. Boige N, Faure C, Cargill G, Mashako L, Cordeiro-Ferreira G, Viarme F, Cezard JP, Navarro J. Manometrical evaluation in visceral neuropathies in children. J Pediatr Gastroenterol Nutr 1994;19:71–77.
  34. Schuffler MD, Pope CE 2nd. Esophageal motor dysfunction in idiopathic intestinal pseudoobstruction. Gastroenterology 1976; 70:677–682.
  35. Hase T, Kodama M, Kishida A, Naka N, Shimadera S, Egawa T, Ohno M, Shimada M. The application of radio-opaque markers prior to ileostomy in an infant with chronic intestinal pseudo-obstruction: report of a case. Surg Today 1998;28:83–86.
  36. Greydanus MP, Camilleri M, Colemont LJ, Phillips SF, Brown ML, Thomforde GM. Ileocolonic transfer of solid chyme in small intestinal neuropathies and myopathies. Gastroenterology 1990; 99:158–164.
  37. Chitkara DK, Delgado-Aros S, Bredenoord AJ, Cremonini F, El-Youssef M, Freese D, Camilleri M. Functional dyspepsia, upper gastrointestinal symptoms, and transit in children. J Pediatr 2003;143:609–613.
  38. Di Lorenzo C, Reddy SN, Flores AF, Hyman PE. Is electrogastrography a substitute for manometric studies in children with functional gastrointestinal disorders? Dig Dis Sci 1997;42:2310– 2316.
  39. Cucchiara S, Borrelli O, Salvia G, Iula VD, Fecarotta S, Gaudiello G, Boccia G, Annese V. A normal gastrointestinal motility excludes chronic intestinal pseudoobstruction in children. Dig Dis Sci 2000;45:258–264.
  40. Feldstein AE, Miller SM, El-Youssef M, Rodeberg D, Lindor NM, Burgart LJ, Szurszewski JH, Farrugia G. Chronic intestinal pseudoobstruction associated with altered interstitial cells of Cajal networks. J Pediatr Gastroenterol Nutr 2003;36:492–497.
  41. Richardson CE, Morgan JM, Jasani B, Green JT, Rhodes J, Williams GT, Lindstrom J, Wonnacott S, Thomas GA, Smith V. Mega-cystis-microcolon-intestinal hypoperistalsis syndrome and the absence of the alpha3 nicotinic acetylcholine receptor subunit. Gastroenterology 2001;121:350–357.
  42. Di Lorenzo C, Reddy SN, Villanueva-Meyer J, Mena I, Martin S, Hyman PE. Cisapride in children with chronic intestinal pseudo-obstruction. An acute, double-blind, crossover, placebo-controlled trial. Gastroenterology 1991;101:1564–1570.
  43. Cucchiara S, Minella R, Scoppa A, Emiliano M, Calabrese F, Az-Zeqeh N, Rea B, Salvia G. Antroduodenal motor effects of intravenous erythromycin in children with abnormalities of gastrointestinal motility. J Pediatr Gastroenterol Nutr 1997;24:411– 418.
  44. Di Lorenzo C, Lucanto C, Flores AF, Idries S, Hyman PE. Effect of sequential erythromycin and octreotide on antroduodenal manometry. J Pediatr Gastroenterol Nutr 1999;29:293–296.
  45. Minami T, Nishibayashi H, Shinomura Y, Matsuzawa Y. Effects of erythromycin in chronic idiopathic intestinal pseudo-obstruction. J Gastroenterol 1996;31:855–859.
  46. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 1991;325:1461–1467.
  47. Gmora S, Poenaru D, Tsai E. Neostigmine for the treatment of pediatric acute colonic pseudo-obstruction. J Pediatr Surg 2002; 37:E28.
  48. Calvet X, Martinez JM, Martinez M. Repeated neostigmine dosage as palliative treatment for chronic colonic pseudo-obstruction in a patient with autonomic paraneoplastic neuropathy. Am J Gastroenterol 2003;98:708–709.
  49. Nieuwenhuijs VB, Verheem A, van Duijvenbode-Beumer H, Visser MR, Verhoef J, Gooszen HG, Akkermans LM. The role of interdigestive small bowel motility in the regulation of gut microflora, bacterial overgrowth, and bacterial translocation in rats. Ann Surg 1998;228:188–193.
  50. Stotzer PO, Bjornsson ES, Abrahamsson H. Interdigestive and postprandial motility in small-intestinal bacterial overgrowth. Scand J Gastroenterol 1996;31:875–880.
  51. Husebye E. Gastrointestinal motility disorders and bacterial overgrowth. J Intern Med 1995;237:419–427.
  52. Cuoco L, Montalto M, Jorizzo RA, Santarelli L, Arancio F, Cammarota G, Gasbarrini G. Eradication of small intestinal bacterial overgrowth and oro-cecal transit in diabetics. Hepatogastroenterology 2002;49:1582–1586.
  53. Madrid AM, Hurtado C, Venegas M, Cumsille F, Defilippi C. Long-term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function. Am J Gastroenterol 2001;96:1251–1255.
  54. Singh VV, Toskes PP. Small bowel bacterial overgrowth: presentation, diagnosis, and treatment. Curr Gastroenterol Rep 2003; 5:365–372.
  55. Hyman PE, Fiske ME, Di Lorenzo C, Diego A. North American Pediatric Pseudo-obstruction Society (NAPPS) survey. Pediatr Res 1993;31:108A.
  56. Anand KJ, Runeson B, Jacobson B. Gastric suction at birth associated with long-term risk for functional intestinal disorders in later life. J Pediatr 2004;144:449–454.
  57. Andrews KA, Desai D, Dhillon HK, Wilcox DT, Fitzgerald M. Abdominal sensitivity in the first year of life: comparison of infants with and without prenatally diagnosed unilateral hydronephrosis. Pain 2002;100:35–46.
  58. Lin C, Al-Chaer ED. Long-term sensitization of primary afferents in adult rats exposed to neonatal colon pain. Brain Res 2003;971: 73–82.
  59. Munakata J, Naliboff B, Harraf F, Kodner A, Lembo T, Chang L, Silverman DH, Mayer EA. Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterology 1997;112:55–63.
  60. Hyman PE, Bursch B, Sood M, Schwankovsky L, Cocjin J, Zeltzer LK. Visceral pain-associated disability syndrome: a descriptive analysis. J Pediatr Gastroenterol Nutr 2002;35:663–668.
  61. Hunt RH, Tougas G. Evolving concepts in functional gastrointestinal disorders: promising directions for novel pharmaceutical treatments. Best Pract Res Clin Gastroenterol 2002;16:869– 883.
  62. Heughan CE, Sawynok J. The interaction between gabapentin and amitriptyline in the rat formalin test after systemic administration. Anesth Analg 2002;94:975–980.
  63. Gottrup H, Juhl G, Kristensen AD, Lai R, Chizh BA, Brown J, Bach FW, Jensen TS. Chronic oral gabapentin reduces elements of central sensitization in human experimental hyperalgesia. Anesthesiology 2004;101:1400–1408.
  64. Gilron I. Is gabapentin a “broad-spectrum” analgesic? Anesthesiology 2002;97:537–539.
  65. Poitras P, Riberdy Poitras M, Plourde V, Boivin M, Verrier P. Evolution of visceral sensitivity in patients with irritable bowel syndrome. Dig Dis Sci 2002;47:914–920.
  66. Mertz H, Fass R, Kodner A, Yan-Go F, Fullerton S, Mayer EA. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 1998;93:160–165.
  67. Michaud L, Guimber D, Carpentier B, Sfeir R, Lambilliotte A, Mazingue F, Gottrand F, Turck D. Gastrostomy as a decompression technique in children with chronic gastrointestinal obstruction. J Pediatr Gastroenterol Nutr 2001;32:82–85.
  68. Murr MM, Sarr MG, Camilleri M. The surgeon’s role in the treatment of chronic intestinal pseudoobstruction. Am J Gastroenterol 1995;90:2147–2151.
  69. Fonkalsrud EW, Pitt HA, Berquist WE, Ament ME. Surgical management of chronic intestinal pseudo-obstruction in infancy and childhood. Prog Pediatr Surg 1989;24:221–225.
  70. Pitt HA, Mann LL, Berquist WE, Ament ME, Fonkalsrud EW, DenBesten L. Chronic intestinal pseudo-obstruction. Management with total parenteral nutrition and a venting enterostomy. Arch Surg 1985;120:614–618.
  71. Shibata C, Naito H, Funayama Y, Fukushima K, Hashimoto A, Kitayama T, Nagao M, Matsuno S, Sasaki I. Surgical treatment of chronic intestinal pseudo-obstruction: report of three cases. Surg Today 2003;33:58–61.
  72. Thompson AR, Pearson T, Ellul J, Simson JN. Percutaneous endoscopic colostomy in patients with chronic intestinal pseudo-obstruction. Gastrointest Endosc 2004;59:113–115.
  73. Nayci A, Avlan D, Polat A, Aksoyek S. Treatment of intestinal pseudo obstruction by segmental resection. Pediatr Surg Int 2003;19:44–46.
  74. Mittal NK, Tzakis AG, Kato T, Thompson JF. Current status of small bowel transplantation in children: update 2003. Pediatr Clin North Am 2003;50:ix, 1419–1433.
  75. Bueno J, Ohwada S, Kocoshis S, Mazariegos GV, Dvorchik I, Sigurdsson L, Di Lorenzo C, Abu-Elmagd K, Reyes J. Factors impacting the survival of children with intestinal failure referred for intestinal transplantation. J Pediatr Surg 1999;34:27–33.
  76. Gambarara M, Diamanti A, Castro M, Knafelz D, Ferretti F, Papa-datou B, D’Orio F. Clinical outcome and etiology of chronic non-malignant intestinal failure: a pediatric series. Transplant Proc 2002;34:3363–3365.
  77. Sigurdsson L, Reyes J, Kocoshis SA, Mazariegos G, Abu-Elmagd KM, Bueno J, Di Lorenzo C. Intestinal transplantation in children with chronic intestinal pseudo-obstruction. Gut 1999;45:570– 574.
  78. Iyer K, Kaufman S, Sudan D, Horslen S, Shaw B, Fox I, Langnas A. Long-term results of intestinal transplantation for pseudo-obstruction in children. J Pediatr Surg 2001;36:174–177.
  79. Lin Z, Chen JD. Advances in gastrointestinal electrical stimulation. Crit Rev Biomed Eng 2002;30:419–457.
  80. Abell TL, Van Cutsem E, Abrahamsson H, Huizinga JD, Konturek JW, Galmiche JP, Voelier G, Filez L, Everts B, Waterfall WE, Domschke W, Bruley des Varannes S, Familoni BO, Bourgeois IM, Janssens J, Tougas G. Gastric electrical stimulation in intractable symptomatic gastroparesis. Digestion 2002;66:204–212.
  81. Abell T, McCallum R, Hocking M, Koch K, Abrahamsson H, Leb-lanc I, Lindberg G, Konturek J, Nowak T, Quigley EM, Tougas G, Starkebaum W. Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology 2003;125:421–428.
  82. Luo J, Al-Juburi A, Rashed H, O’Dorisio T, Marchal B, Starkebaum W, Abell TL. Gastric electrical stimulation is associated with imiprovement in pancreatic exocrine function in humans. Pancreas 2004;29:e41–e44.
  83. Abell T, Lou J, Tabbaa M, Batista O, Malinowski S, Al-Juburi A. Gastric electrical stimulation for gastroparesis improves nutritional parameters at short, intermediate, and long-term follow-up. JPEN J Parenter Enteral Nutr 2003;27:277–281.
  84. Friedenberg F, Gollamudi S, Parkman HP. The use of botulinum toxin for the treatment of gastrointestinal motility disorders. Dig Dis Sci 2004;49:165–175.
  85. Yokota T, Suda T, Tsukioka S, Takahashi T, Honma T, Seki K, Matsuzawa J, Miura M, Aoyagi Y, Asakura H. The striking effect of hyperbaric oxygenation therapy in the management of chronic idiopathic intestinal pseudo-obstruction. Am J Gastroenterol 2000;95:285–288.
  86. Mousa H, Hyman PE, Cocjin J, Flores AF, Di Lorenzo C. Long-term outcome of congenital intestinal pseudoobstruction. Dig Dis Sci 2002;47:2298–2305.
  87. Schwankovsky L, Mousa H, Rowhani A, Dil C, Hyman PE. Quality of life outcomes in congenital chronic intestinal pseudo-obstruction. Dig Dis Sci 2002;47:1965–1968.
  88. Moreno JM, Gomis P. Pregnancy in a patient with chronic intestinal failure on long-term parenteral nutrition. Clin Nutr 2002;21: 438–440.
  89. Pendlebury J, Phillips F, Ferguson A, Ghosh S. Successful pregnancy in a patient with chronic intestinal pseudo-obstruction while on ambulatory percutaneous endoscopic gastrostomy feeding. Eur J Gastroenterol Hepatol 1997;9:711–713.

Received September 17, 2004. Accepted June 6, 2005.

Address requests for reprints to: Carlo Di Lorenzo, MD, Division of Pediatric Gastroenterology, Children’s Hospital of Columbus, 700 Children’s Drive, Columbus, Ohio 43205. e-mail: dilorenc@pediatrics.ohio-state.edu; fax: (614) 722-3454.



Назад в раздел
Популярно о болезнях ЖКТ читайте в разделе "Пациентам"
Лекарства, применяемые при заболеваниях ЖКТ
Адреса клиник

Индекс цитирования
Логотип Исток-Системы

Информация на сайте www.gastroscan.ru предназначена для образовательных и научных целей. Условия использования.